Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multi-center, Open-label, Dose Finding Study of CC-92328 in Subjects With Relapsed and/or Refractory Multiple Myeloma

NCT04975399 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT04975399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04975399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multi-center, Open-label, Dose Finding Study of CC-92328 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Terminated
Start date
October 5, 2021
Completion date
June 18, 2024
Enrollment
26 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma